Laura Brege - 12 Jan 2023 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
Director
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Issuer symbol
ACAD
Transactions as of
12 Jan 2023
Net transactions value
-$15,500
Form type
4
Filing time
17 Jan 2023, 16:17:32 UTC
Previous filing
28 Jun 2022
Next filing
05 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise $212,625 +12,500 $17.01 12,500 12 Jan 2023 Direct
transaction ACAD Common Stock Sale $228,125 -12,500 -100% $18.25 0 12 Jan 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Stock Option (Right to Buy) Options Exercise $0 -12,500 -100% $0.000000* 0 12 Jan 2023 Common Stock 12,500 $17.01 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2022.
F2 The option is fully vested and exercisable.